06.15.20

Panel Addresses the Use of MRD in Clinical Decision Making

The clinical challenges surrounding the management of patients who are persistently MRD positive – in particular, whether and when to make the decision to proceed to transplantation – was one of the topics tackled by a panel of experts in adult and pediatric leukemia at a recent OncLive Peer Exchange®.

The panelists also reviewed published and emerging data on the clinical use of blinatumomab (Blincyto), the first and so far only bispecific T-cell engager to gain FDA approval, and shared their thoughts on how to optimally use this agent in the MRD-positive population with B-cell precursor acute lymphoblastic leukemia.

Theme picker

Search